

APPLICATION DATA SHEET UNDER 37 C.F.R. § 1.76

Applicant Information

- (a) Name: Yoshitaka Ichikawa  
Residence: San Diego, CA, USA  
Mailing Address: 4848 Algonquin Court, San Diego, CA 92130,  
USA  
Nationality: Japan
- (b) Name: Youe-Kong Shue  
Residence: Carlsbad, CA, USA  
Mailing Address: 7869 Via Teca, Carlsbad, CA 92130, USA  
Nationality: USA
- (c) Name: Norman K. Orida  
Residence: San Diego, CA, USA  
Mailing Address: 12867 Corbett Court, San Diego, CA 92130,  
USA  
Nationality: USA
- (d) Name: Martin Lotz  
Residence: La Jolla, CA, USA  
Mailing Address: P.O. Box 1513, La Jolla, CA 92038, USA  
Nationality: DE
- (e) Chi-Huey Wong  
Residence: Rancho Santa Fe, CA , USA  
Mailing Address: 6399 Calle Del Alcazar, Lot 209, Rancho Santa  
Fe, CA 92067, USA  
Nationality: USA

- (f) Name: Franklin W. Okumu  
Residence: San Diego, CA, USA  
Mailing Address: 3649 Victor Avenue, Oakland, CA 94619, USA  
(This inventor's address has changed from that stated on the PCT application at 3066 Palm Street, San Diego, CA 92104, USA)  
Nationality: USA
- (g) San-Bao Hwang  
Residence: Danshui, Taiwan  
Mailing Address: No. 174 Ba Shr Road Sect. 1, Danshui, Taiwan  
Nationality: USA

Correspondence Information

Catalyst Law Group, APC  
Customer Number: 32301

Application Information

- (a) Title: Treatment of Degenerative Cartilage Conditions in a Mammal with Glycosidase Inhibitors"
- (b) Total Number of Specification Pages: 25
- (c) Total Number of Claims Pages: 4
- (d) Total Number of Drawing Sheets: 3
- (e) Total Number of Abstract Pages: 1
- (f) Attorney Docket Number: 8031-014-US

- (g) Type of Application: Utility Application under 35 U.S.C. § 371.
- (h) Status of Disclosure of Information from Application under a Secrecy Order: No disclosure of any information from any application under secrecy order.

Representative Information

Customer Number: 32301

Priority Information

Priority under 35 U.S.C. §§ 119 and 365 is hereby claimed for the national stage application. This priority is claimed to: (1) PCT Application No. PCT/US2005/002017, filed on January 20, 2005, and designating the United States; and (2) United States Provisional Patent Application Serial No. 60/531,168 filed on January 20, 2004, from which PCT Application No. PCT/US2005/002017 claimed priority.

Assignee Information:

- a) Optimer Pharmaceuticals, Inc., 10110 Sorrento Valley Road, Suite C, San Diego, CA 92121; and
- b) The Scripps Research Institute, 10550 North Torrey Pines Road La Jolla, CA 92037.